Bevacizumab-induced hand-foot syndrome: circumscribed typeMUNEHIRO, A; YONEDA, K; YOKOMISE, H et al.British journal of dermatology (1951). 2010, Vol 162, Num 6, pp 1411-1413, issn 0007-0963, 3 p.Article

Injections sous-conjonctivales de bévacizumab dans le traitement de la néovascularisation cornéenne = Subconjunctival bevacizumab for corneal neovascularizationGUEUDRY, J; RICHEZ, F; TOUGERON-BROUSSEAU, B et al.Journal français d'ophtalmologie. 2010, Vol 33, Num 9, pp 630-636, issn 0181-5512, 7 p.Article

Bevacizumab 5 mg/kg can be infused safely over 10 minutesREIDY, Diane L; CHUNG, Ki Y; TIMONEY, John P et al.Journal of clinical oncology. 2007, Vol 25, Num 19, pp 2691-2695, issn 0732-183X, 5 p.Article

Bevacizumab : current status and future directionsMIDGLEY, Rachel; KERR, David.Annals of oncology. 2005, Vol 16, Num 7, pp 999-1004, issn 0923-7534, 6 p.Article

CAN PEROPERATIVE BEVACIZUMAB IMPROVE TRABECULECTOMY OUTCOME? AVASTIN-TRAB STUDY : 2009 FRO PROJECTSVANDEWALLE, E; SPIELBERG, L; ZEYEN, T et al.Bulletin de la Société belge d'ophtalmologie. 2010, Num 314, pp 51-52, issn 0081-0746, 2 p.Article

Predictive Biomarkers for Bevacizumab: Are We There Yet?MARU, Dipen; VENOOK, Alan P; ELLIS, Lee M et al.Clinical cancer research (Print). 2013, Vol 19, Num 11, pp 2824-2827, issn 1078-0432, 4 p.Article

Bevacizumab for Malignant GliomasIWAMOTO, Fabio M; FINE, Howard A.Archives of neurology (Chicago). 2010, Vol 67, Num 3, pp 285-288, issn 0003-9942, 4 p.Article

Bevacizumab in older patients and patients with poorer performance statusHOFF, Paulo M.Seminars in oncology. 2006, Vol 33, Num 5, issn 0093-7754, S19-S25, SUP10Article

Exudative, Nonhealing Scalp: A Complication of Systemic Chemotherapy With Capecitabine and BevacizumabBLACK, Jeanette M; HODARI, Kafele T; ROGERS, Nicole et al.Archives of dermatology (1960). 2011, Vol 147, Num 1, pp 134-135, issn 0003-987X, 2 p.Article

Tumeurs cérébrales primitives rares et thérapies cibléesTAILLIBERT, Sophie.Neurologie.com. 2010, Vol 2, pp 27-28, issn 2100-9511, 2 p., NS1Article

Clinical, legal and ethical implications of the intra-ocular (off-label) use of bevacizumab (Avastin) ― a South African perspectiveJANSEN, Rita-Marié; GOUWS, Chris.SAMJ. South African medical journal. 2009, Vol 99, Num 6, pp 446-449, issn 0256-9574, 4 p.Article

Bevacizumab Use for Recurrent High- Grade Glioma at McGill University HospitalSAHEBJAM, Solmaz; GAROUFALIS, Evgenia; GUIOT, Marie-Christine et al.Canadian journal of neurological sciences. 2013, Vol 40, Num 2, pp 241-246, issn 0317-1671, 6 p.Article

Erythrodermic Psoriasis Improved by Panitumumab, But Not BevacizumabNISHIZAWA, Aya; SATOH, Takahiro; YOKOZEKI, Hiroo et al.Acta dermato-venereologica. 2012, Vol 92, Num 4, pp 360-361, issn 0001-5555, 2 p.Article

Platelets take up the monoclonal antibody bevacizumabVERHEUL, Henk M. W; LOLKEMA, Martijn P. J; QIAN, David Z et al.Clinical cancer research. 2007, Vol 13, Num 18, pp 5341-5347, issn 1078-0432, 7 p., 1Article

Traitement du glaucome néovasculaire en 2012: apport des anti-VEGF = Neovascular glaucoma treatment in 2012: Role of anti-VEGF agentsKODJIKIAN, L.Journal français d'ophtalmologie. 2013, Vol 36, Num 5, pp 461-465, issn 0181-5512, 5 p.Conference Paper

Antiangiogenic Therapy for Cancer: An UpdateAL-HUSEIN, Belal; ABDALLA, Maha; TREPTE, Morgan et al.Pharmacotherapy. 2012, Vol 32, Num 12, pp 1095-1111, issn 0277-0008, 17 p.Article

Bevacizumab for Recurrent Alkylator-Refractory Anaplastic OligodendrogliomaCHAMBERLAIN, Marc C; JOHNSTON, Sandra.Cancer. 2009, Vol 115, Num 8, pp 1734-1743, issn 0008-543X, 10 p.Article

Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d'une étude multicentrique de l'Anocef = Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas : Preliminary results of an ANOCEF Multicenter StudyGUIU, S; TAILLIBERT, S; CAPELLE, F et al.Revue neurologique (Paris). 2008, Vol 164, Num 6-7, pp 588-594, issn 0035-3787, 7 p.Article

Absence of intravitreal bevacizumab-induced neuronal toxicity in the retinaJEONG HUN KIM; KIM, Cinoo; JIN HYOUNG KIM et al.Neurotoxicology (Park Forest South). 2008, Vol 29, Num 6, pp 1131-1135, issn 0161-813X, 5 p.Article

Vasodilation to PTH (1-84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signalingPRISBY, Rhonda; MENEZES, Thomas; CAMPBELL, Jeremiah et al.Bone (New York, NY). 2013, Vol 54, Num 1, pp 68-75, issn 8756-3282, 8 p.Article

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesotheliomaDOWELL, Jonathan E; DUNPHY, Frank R; TAUB, Robert N et al.Lung cancer. 2012, Vol 77, Num 3, pp 567-571, issn 0169-5002, 5 p.Article

Timing of Administration of Bevacizumab Chemotherapy Affects Wound Healing After Chest Wall Port PlacementERINJERI, Joseph P; FONG, Abigail J; KEMENY, Nancy E et al.Cancer. 2011, Vol 117, Num 6, pp 1296-1301, issn 0008-543X, 6 p.Article

Toxicité inhabituelle du bevacizumab (Avastin^®): hyperlipémie ? = Unusual toxicity of bevacizumab (Avastin^®): hyperlipemia?MOHAMED REDA KHMAMOUCHE; SBITTI, Yassir; MAHFOUD, Tarik et al.Cancéro digest. 2011, Vol 3, Num 1, pp 46-48, issn 1953-5171, 3 p.Article

Évaluation de la fatigue dans les glioblastomes en récidive traités par l'association irinotécan-bévacizumab = An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumabDEHAIS, C; SOUVANNAVONG, V; NGUYEN, B. K et al.Revue neurologique (Paris). 2011, Vol 167, Num 11, pp 841-846, issn 0035-3787, 6 p.Article

Bevacizumab for neovascular ocular diseasesLYNCH, Shalini S; CHENG, Christine M.The Annals of pharmacotherapy. 2007, Vol 41, Num 4, pp 614-625, issn 1060-0280, 12 p.Article